Coya Therapeutics, Common Stock Current Valuation
| COYA Stock | 6.38 0.12 1.85% |
Valuation analysis of Coya Therapeutics, Common helps investors to measure Coya Therapeutics,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value Over EBITDA is expected to grow to -5.13. The current year's Enterprise Value Multiple is expected to grow to -5.13. Fundamental drivers impacting Coya Therapeutics,'s valuation include:
Price Book 3.33 | Enterprise Value 122.4 M | Enterprise Value Ebitda (6.21) | Price Sales 11.1566 | Enterprise Value Revenue 12.8129 |
Overvalued
Today
Please note that Coya Therapeutics,'s price fluctuation is relatively risky at this time. Calculation of the real value of Coya Therapeutics, Common is based on 3 months time horizon. Increasing Coya Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Coya Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Coya Stock. However, Coya Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.38 | Real 6.04 | Target 13.0 | Hype 6.38 | Naive 7.28 |
The real value of Coya Stock, also known as its intrinsic value, is the underlying worth of Coya Therapeutics, Common Company, which is reflected in its stock price. It is based on Coya Therapeutics,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Coya Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Coya Therapeutics, Common helps investors to forecast how Coya stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Coya Therapeutics, more accurately as focusing exclusively on Coya Therapeutics,'s fundamentals will not take into account other important factors: Coya Therapeutics, Common Company Current Valuation Analysis
Coya Therapeutics,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Coya Therapeutics, Current Valuation | 122.42 M |
Most of Coya Therapeutics,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Coya Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Coya Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Coya Therapeutics, is extremely important. It helps to project a fair market value of Coya Stock properly, considering its historical fundamentals such as Current Valuation. Since Coya Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Coya Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Coya Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Coya Current Valuation Historical Pattern
Today, most investors in Coya Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Coya Therapeutics,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Coya Therapeutics, current valuation as a starting point in their analysis.
Coya Therapeutics, Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Coya Therapeutics, Common has a Current Valuation of 122.42 M. This is 99.15% lower than that of the Biotechnology sector and 97.36% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.26% higher than that of the company.
Coya Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coya Therapeutics,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coya Therapeutics, could also be used in its relative valuation, which is a method of valuing Coya Therapeutics, by comparing valuation metrics of similar companies.Coya Therapeutics, is currently under evaluation in current valuation category among its peers.
Coya Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Coya Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Coya Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Coya Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.17) % | ||||
| Current Valuation | 122.42 M | ||||
| Shares Outstanding | 16.71 M | ||||
| Shares Owned By Insiders | 7.03 % | ||||
| Shares Owned By Institutions | 19.96 % | ||||
| Number Of Shares Shorted | 196.52 K | ||||
| Price To Book | 3.33 X | ||||
| Price To Sales | 11.16 X | ||||
| Revenue | 6 M | ||||
| EBITDA | (7.9 M) | ||||
| Net Income | (7.99 M) | ||||
| Total Debt | 5.63 M | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (11.19 M) | ||||
| Short Ratio | 1.27 X | ||||
| Earnings Per Share | (0.65) X | ||||
| Target Price | 15.63 | ||||
| Market Capitalization | 106.59 M | ||||
| Total Asset | 41.26 M | ||||
| Retained Earnings | (25.86 M) | ||||
| Working Capital | 36.14 M | ||||
| Net Asset | 41.26 M |
About Coya Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coya Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coya Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coya Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:Check out Coya Therapeutics, Piotroski F Score and Coya Therapeutics, Altman Z Score analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.687 | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.